Cosmos Health Intends to Resume Share Repurchases as Insiders Agree to 12-Month Lock-Up
Cosmos Health plans to resume open-market share repurchases, with approximately $3.85 million remaining under its authorised programme. Company executives and directors have also agreed to a 12-month lock-up on shares they hold.
Cosmos Health Inc. (NASDAQ:COSM) said on November 19, 2026, that it intends to restart open-market purchases of its common stock under a $5.0 million repurchase programme. At the same time, the company’s executive officers and Board of Directors members have agreed not to sell or otherwise dispose of the shares they hold for 12 months.
The announcement describes two separate actions: a planned resumption of company share purchases and a lock-up commitment covering shares held by senior leadership and directors.
The programme was authorised by Cosmos Health’s Board of Directors on June 26, 2026. The company said it has so far repurchased 255,600 shares, or 5,112,000 pre-split, for approximately $1.15 million. Approximately $3.85 million remains available under the programme.
Any further purchases may take place from time to time in the open market and must comply with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Cosmos Health said the timing and amount of repurchases will depend on market conditions and other factors. The programme may also be suspended or discontinued at any time.
Cosmos Health said its executive officers and Board members have agreed to retain the common stock they hold for 12 months, subject to the terms of their commitment. During that period, they have agreed not to sell or otherwise dispose of those shares.
The company identified Greg Siokas as its chief executive officer. In comments accompanying the announcement, Siokas cited the company’s strengthened balance sheet, record nine-month revenue and new growth engines, including an expanding subscription model. He said Cosmos Health believes it is well positioned, while the release also noted that forward-looking statements involve risks and uncertainties.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. Its activities include pharmaceutical and nutraceutical brands, manufacturing through Cana Laboratories S.A., distribution of pharmaceuticals and parapharmaceuticals in Greece and the UK, research and development, and telehealth operations through ZipDoctor, Inc.
The company said it is expanding across Europe, Asia and North America. It has offices and distribution centres in Thessaloniki and Athens, Greece, and Harlow, UK.
Cosmos Health announced that it intends to resume open-market share repurchases under its $5.0 million programme and that its executive officers and Board members have agreed to a 12-month lock-up on the shares of the Company's common stock they hold.
Cosmos Health made the announcement on November 19, 2026, and the lock-up covers a period of 12 months. The Company said its leadership intends not to sell or otherwise dispose of the shares they hold during that period.
Approximately $3.85 million remains available under Cosmos Health's $5.0 million share repurchase programme. The programme was authorised by the Company's Board of Directors on June 26, 2026.
Cosmos Health said it has repurchased a total of 255,600 shares, or 5,112,000 pre-split, for approximately $1.15 million.
Cosmos Health said repurchases may be made from time to time in the open market in accordance with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. The timing and amount will depend on market conditions and other factors.
Yes. Cosmos Health said the repurchase programme may be suspended or discontinued at any time.
The Company's executive officers and members of its Board of Directors have agreed not to sell or otherwise dispose of the shares of Cosmos Health's common stock they hold for 12 months.
Greg Siokas said Cosmos Health was putting the Company's capital and management's own shares behind its conviction in the Company. He said resuming the buyback and committing officers and the Board to a 12-month lock-up reflected the leadership's stated intention to remain invested for the long term.
Greg Siokas said Cosmos Health believes it is well positioned, citing what he described as a strengthened balance sheet, record nine-month revenue and new growth engines including an expanding subscription model. The release states that forward-looking matters involve risks and uncertainties, including financing, regulatory, international-market, litigation and execution risks, and that actual results could differ materially from expectations and projections.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. It owns pharmaceutical and nutraceutical brands, manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices through Cana Laboratories S.A., distributes pharmaceuticals and parapharmaceuticals in Greece and the UK, conducts research and development, and operates in telehealth through ZipDoctor, Inc.
Cosmos Health's shares are listed on NASDAQ under the ticker symbol COSM.
Cosmos Health said it is expanding throughout Europe, Asia and North America, with offices and distribution centres in Thessaloniki and Athens, Greece, and Harlow, UK.